JP2018501247A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501247A5 JP2018501247A5 JP2017533220A JP2017533220A JP2018501247A5 JP 2018501247 A5 JP2018501247 A5 JP 2018501247A5 JP 2017533220 A JP2017533220 A JP 2017533220A JP 2017533220 A JP2017533220 A JP 2017533220A JP 2018501247 A5 JP2018501247 A5 JP 2018501247A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- antibody
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094944P | 2014-12-19 | 2014-12-19 | |
| US62/094,944 | 2014-12-19 | ||
| PCT/US2015/066400 WO2016100679A1 (en) | 2014-12-19 | 2015-12-17 | Immunotherapy treatments and compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018501247A JP2018501247A (ja) | 2018-01-18 |
| JP2018501247A5 true JP2018501247A5 (enExample) | 2019-01-10 |
| JP6649953B2 JP6649953B2 (ja) | 2020-02-19 |
Family
ID=56127600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533220A Expired - Fee Related JP6649953B2 (ja) | 2014-12-19 | 2015-12-17 | 免疫療法による治療および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10624965B2 (enExample) |
| EP (1) | EP3233104B1 (enExample) |
| JP (1) | JP6649953B2 (enExample) |
| AU (1) | AU2015364559B2 (enExample) |
| CA (1) | CA2971471C (enExample) |
| DK (1) | DK3233104T3 (enExample) |
| ES (1) | ES2781673T3 (enExample) |
| WO (1) | WO2016100679A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018039132A1 (en) * | 2016-08-24 | 2018-03-01 | Wisconsin Alumni Research Foundation | Methods and compositions for the treatment of cancer |
| CA3086751A1 (en) * | 2018-01-08 | 2019-07-11 | Susavion Biosciences, Inc. | Compositions and methods of treating cancer with glycomimetic peptides |
| WO2022026092A2 (en) * | 2020-07-28 | 2022-02-03 | Susavion Biosciences, Inc. | Method of treatment of neutrophil-driven inflammatory pathologies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005087793A2 (en) | 2004-02-05 | 2005-09-22 | The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Immunostimulatory compositions and uses thereof |
| US7838497B2 (en) | 2006-12-13 | 2010-11-23 | Susavion Biosciences, Inc. | Pro-angiogenic peptides |
| US8168757B2 (en) * | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| JP5797190B2 (ja) * | 2009-05-15 | 2015-10-21 | アイ アール エックス セーラピューティクス， インコーポレイテッド | ワクチン免疫療法 |
| GB0920258D0 (en) * | 2009-11-19 | 2010-01-06 | Alligator Bioscience Ab | New medical agents and use thereof |
| WO2013096829A2 (en) | 2011-12-22 | 2013-06-27 | Arizona Biomedical Research Commission | Activation of cellular assault processes in the treatment of glioblastoma multiforme |
| AU2013263076B2 (en) * | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| CA2884704C (en) | 2012-09-07 | 2023-04-04 | Randolph J. Noelle | Vista modulators for diagnosis and treatment of cancer |
-
2015
- 2015-12-17 US US15/537,731 patent/US10624965B2/en active Active
- 2015-12-17 ES ES15871075T patent/ES2781673T3/es active Active
- 2015-12-17 JP JP2017533220A patent/JP6649953B2/ja not_active Expired - Fee Related
- 2015-12-17 AU AU2015364559A patent/AU2015364559B2/en not_active Ceased
- 2015-12-17 DK DK15871075.6T patent/DK3233104T3/da active
- 2015-12-17 CA CA2971471A patent/CA2971471C/en active Active
- 2015-12-17 EP EP15871075.6A patent/EP3233104B1/en active Active
- 2015-12-17 WO PCT/US2015/066400 patent/WO2016100679A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kudarha et al. | Albumin based versatile multifunctional nanocarriers for cancer therapy: Fabrication, surface modification, multimodal therapeutics and imaging approaches | |
| Butowski et al. | A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05) | |
| Brunsvig et al. | Long-term outcomes of a phase I study with UV1, a second generation telomerase based vaccine, in patients with advanced non-small cell lung cancer | |
| JP2016530323A5 (enExample) | ||
| RU2016148645A (ru) | Антитела к в7-н1 и к ctlа-4 для лечения немелкоклеточного рака легкого | |
| Sayour et al. | Manipulation of innate and adaptive immunity through cancer vaccines | |
| RU2018105985A (ru) | Новый подход к лечению рака с применением иммуномодуляции | |
| JP2019504892A5 (enExample) | ||
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP7780444B2 (ja) | ＩＦＮ－γの抗腫瘍補助薬の調製への応用 | |
| JP2017506662A5 (enExample) | ||
| CN108392633A (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| Li et al. | Boosting CAR-T cell therapy through vaccine synergy | |
| EP3371210B1 (en) | Combination therapy for malignant diseases | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| CN106540256A (zh) | 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用 | |
| Skalickova et al. | Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer | |
| WO2015131176A1 (en) | Compositions, methods, and kits for treatment of cancer | |
| US20160340650A1 (en) | Blood derived immune stimulatory compositions | |
| Liu et al. | Cancer biotherapy: review and prospect | |
| Schneider et al. | Use of HER2-specific chimeric antigen receptor-modified virus-specific T cells as a potential therapeutic for progressive HER2-positive glioblastoma | |
| JP2021504329A5 (enExample) | ||
| CN109674788B (zh) | 羧胺三唑与ido1抑制剂组合在抗肿瘤中的用途 | |
| Young et al. | Ideal timing of immunotherapy with radiation in murine tumor models | |
| Liu et al. | The enhanced cancer nanovaccine by bidirectionally blocking CXCL12/CXCR4 axis to inhibit the recurrence and metastasis of triple-negative breast cancer |